Drug survival of apremilast in patients treated for psoriasis in a real-world setting

被引：19
|
作者：
Lee, Erica B. [1 ]
Amin, Mina [2 ,4 ]
Wu, Jashin J. [3 ]
机构：
[1] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA
[2] Univ Calif Riverside, Sch Med, Riverside, CA 92521 USA
[3] Kaiser Permanente Los Angeles, Dept Dermatol, Med Ctr, 1515 North Vermont Ave,5th Floor, Los Angeles, CA 90027 USA
[4] Kaiser Permanente Los Angeles, Dept Med, Med Ctr, Los Angeles, CA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2018年 / 79卷 / 04期
关键词：
ORAL PHOSPHODIESTERASE-4 INHIBITOR; SEVERE PLAQUE PSORIASIS; CONTROLLED-TRIAL; PHASE-III; EFFICACY; MODERATE; SAFETY;
D O I：
10.1016/j.jaad.2018.03.028
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：760 / 761
页数：3
相关论文
共 50 条
  • [41] Real-world experience of apremilast as a treatment choice for chronic plaque psoriasis from a district general hospital setting
    Hadjieconomou, S.
    Hughes, J.
    Kamath, S.
    Li, V.
    Rajan, S.
    Haebich, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (01) : E36 - E37
  • [42] Patient-reported insights from the APPRECIATE study: real-world experience of psoriasis patients treated with apremilast in the UK and Ireland
    Shams, K.
    Laws, P.
    Chen, K. S.
    Cordey, M.
    Kleyn, C. Elise
    Griffiths, C. E. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 : 29 - 30
  • [43] Real-world experience with apremilast in patients with psoriasis: interim analysis of 104 patients from the APPRECIATE study
    Kleyn, E.
    Radtke, M.
    Bundy, C.
    Eyerich, K.
    Stahle, M.
    Cordey, M.
    Koscielny, V.
    Griffiths, C. E. M.
    Augustin, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : E244 - E244
  • [44] Improved Quality of Life in Patients with Psoriasis Receiving Apremilast: Real-World Data from the Netherlands
    Juul M. P. A. van den Reek
    Robert J. T. van der Leest
    Sarah E. Thomas
    Ruud Prevoo
    Margreet E. Plantenga
    Elke M. G. J. de Jong
    Advances in Therapy, 2024, 41 : 1594 - 1605
  • [45] Using real-world drug utilization to estimate tumor necrosis factor blocker cost for treated psoriasis patients in a managed care setting
    Bonafede, Machaon
    Watson, Crystal
    Fox, Kathleen
    Gandra, Shravanthi
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB206 - AB206
  • [46] Improved Quality of Life in Patients with Psoriasis Receiving Apremilast: Real-World Data from the Netherlands
    van den Reek, Juul M. P. A.
    van der Leest, Robert J. T.
    Thomas, Sarah E.
    Prevoo, Ruud
    Plantenga, Margreet E.
    de Jong, Elke M. G. J.
    ADVANCES IN THERAPY, 2024, 41 (04) : 1594 - 1605
  • [47] Real-world experience of apremilast
    Fremlin, G. A.
    Bedlow, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 : 63 - 63
  • [48] Real-World Experience With Apremilast: Analysis of Patients From the APPRECIATE Study With Specific Manifestations of Psoriasis
    Griffith, C.
    Kleyn, C. E.
    Radtke, M.
    Stahle, M.
    Sator, P-G
    Conrad, C.
    Eyerich, K.
    Pinter, A.
    Wilsmann-Theis, D.
    Peter, R-U
    Schneider, J.
    Bundy, C.
    Morys, S.
    Cordey, M.
    Koscielny, V
    Augustin, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 122 - 123
  • [49] Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis
    Papadavid, E.
    Rompoti, N.
    Theodoropoulos, K.
    Kokkalis, G.
    Rigopoulos, D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (07) : 1173 - 1179
  • [50] Four-year drug survival of apremilast in patients with psoriasis
    Kishimoto, Megumi
    Komine, Mayumi
    Kamiya, Koji
    Sugai, Junichi
    Kuwahara, Aya
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2023, 50 (07): : 960 - 963
12345